BioSpace News Archive

OncoSec Medical Incorporated (“OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of new data in Clinical Cancer Research which highlighted TAVO™ (intratumoral plasmid IL-12 with electroporation) as a safe, feasibility and clinically meaningful therapy in patients with Merkel cell carcinoma (MCC), an aggressive form of skin cancer.

2019 financial results and provide an update on the company’s business and outlook on Tuesday, October 29, 2019 at 4:30 p.m. (ET) after closing of the market.

OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics.

Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019.

The National Institute on Drug Abuse (NIDA) has awarded a grant to EicOsis LLC as part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative) to support human clinical trials of a novel compound that has been found effective for the treatment of pain in preclinical animal studies

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis, announced the publication of a study evaluating the use of a positron emission tomography (PET) tracer for the detection of idiopathic pulmonary fibrosis (IPF) through the recognition of protein integrin avb6.

Agilent Technologies Inc. (NYSE: A) today introduced a micro gas chromatograph that is small, fast, smart, and easy to use.

Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.

DermTech, Inc. announced its inclusion in Clinical Management Recommendations, “Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Process Assessment” published in the September issue of SKIN.

This partnership will significantly widen Trialbee’s service offerings to drive patient recruitment and retention